47P - Ethnic differences in copper transporter CTR1 expression and tissue platinum concentration in NSCLC

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Lung and other Thoracic Tumours
Translational Research
Presenter Eric Kim
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors E.S. Kim1, X. Tang2, C. Chow3, J. Fujimoto4, N. Kalhor3, S.G. Swisher5, D.J. Stewart6, I. Wistuba2, Z.H. Siddik7
  • 1Wilmot Cancer Center, University of Rochester, Rochester - NY/US
  • 2Translational Molecular Pathology, MD Anderson Cancer Center, Houston/US
  • 3Pathology, MD Anderson Cancer Center, Houston/US
  • 4Thoracic And Hn Oncology, MD Anderson Cancer Center, Houston/US
  • 5Thoracic Surgery, MD Anderson Cancer Center, Houston/US
  • 6The Ottawa Hospital Cancer Center, The University of Ottawa, Ottawa/CA
  • 7Experimental Therapeutics, MD Anderson Cancer Center, Houston/US


African Americans (AAs) have lower lung cancer survival rates compared to Caucasian Americans (CAs). A recent study using ethnically-defined lymphoblastoid cell lines demonstrated that CAs were significantly more sensitive to cisplatin compared with AAs. Furthermore, African-American ethnicity was independently prognostic of poor tumor response to cisplatin in patients with advanced cervical cancer. We previously demonstrated that low tissue platinum (Pt) concentration and undetectable CTR1 (a Pt uptake transporter) level in NSCLC tumor specimens were significantly associated with reduced tumor response following Pt-based therapy. We hypothesized that NSCLC specimens from CAs would have higher CTR1 expression level and intratumoral Pt concentrations.